Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
Status:
Completed
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Venous thromboembolism affects around 10 million people per year worldwide, however, despite
its high incidence, there is no systematic review or randomized trial focused on the
treatment of patients with recurrent deep vein thrombosis (DVT) and/or or pulmonary embolism
(PE) during anticoagulant treatment. The objective was to compare the use of Rivaroxaban plus
Aspirin versus Acenocoumarol in patients with recurrent venous thromboembolism treated with
rivaroxaban.